Cargando…

Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin

Heart failure (HF) is associated with a high morbidity and mortality burden. In light of more recent evidence, SGLT2 inhibitors are currently recommended as first-line therapy in managing patients with HF, regardless of ejection fraction, to reduce HF burden. The DAPA-HF and DELIVER trials, and part...

Descripción completa

Detalles Bibliográficos
Autores principales: Escobar, Carlos, Pascual-Figal, Domingo, Manzano, Luis, Nuñez, Julio, Camafort, Miguel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649290/
https://www.ncbi.nlm.nih.gov/pubmed/37959263
http://dx.doi.org/10.3390/jcm12216798
_version_ 1785135532897992704
author Escobar, Carlos
Pascual-Figal, Domingo
Manzano, Luis
Nuñez, Julio
Camafort, Miguel
author_facet Escobar, Carlos
Pascual-Figal, Domingo
Manzano, Luis
Nuñez, Julio
Camafort, Miguel
author_sort Escobar, Carlos
collection PubMed
description Heart failure (HF) is associated with a high morbidity and mortality burden. In light of more recent evidence, SGLT2 inhibitors are currently recommended as first-line therapy in managing patients with HF, regardless of ejection fraction, to reduce HF burden. The DAPA-HF and DELIVER trials, and particularly, the pooled analysis of both studies, have shown that dapagliflozin significantly reduces the risk of cardiovascular death, all-cause death, total HF hospitalizations, and MACE in the whole spectrum of HF, with sustained benefits over time. Recent data have shown that the full implementation of dapagliflozin in clinical practice would translate into a robust reduction in hospitalizations for HF and death in real-life populations. Many pathophysiological mechanisms have been involved in these benefits, particularly the positive effects of dapagliflozin on reversing cardiac (atrial and ventricular) remodeling, reducing cardiac fibrosis and inflammation, and improving endothelial dysfunction. In this manuscript, we reviewed from a practical point of view the role of dapagliflozin in the management of the whole spectrum of patients with HF.
format Online
Article
Text
id pubmed-10649290
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106492902023-10-27 Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin Escobar, Carlos Pascual-Figal, Domingo Manzano, Luis Nuñez, Julio Camafort, Miguel J Clin Med Review Heart failure (HF) is associated with a high morbidity and mortality burden. In light of more recent evidence, SGLT2 inhibitors are currently recommended as first-line therapy in managing patients with HF, regardless of ejection fraction, to reduce HF burden. The DAPA-HF and DELIVER trials, and particularly, the pooled analysis of both studies, have shown that dapagliflozin significantly reduces the risk of cardiovascular death, all-cause death, total HF hospitalizations, and MACE in the whole spectrum of HF, with sustained benefits over time. Recent data have shown that the full implementation of dapagliflozin in clinical practice would translate into a robust reduction in hospitalizations for HF and death in real-life populations. Many pathophysiological mechanisms have been involved in these benefits, particularly the positive effects of dapagliflozin on reversing cardiac (atrial and ventricular) remodeling, reducing cardiac fibrosis and inflammation, and improving endothelial dysfunction. In this manuscript, we reviewed from a practical point of view the role of dapagliflozin in the management of the whole spectrum of patients with HF. MDPI 2023-10-27 /pmc/articles/PMC10649290/ /pubmed/37959263 http://dx.doi.org/10.3390/jcm12216798 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Escobar, Carlos
Pascual-Figal, Domingo
Manzano, Luis
Nuñez, Julio
Camafort, Miguel
Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin
title Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin
title_full Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin
title_fullStr Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin
title_full_unstemmed Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin
title_short Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin
title_sort current role of slgt2 inhibitors in the management of the whole spectrum of heart failure: focus on dapagliflozin
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649290/
https://www.ncbi.nlm.nih.gov/pubmed/37959263
http://dx.doi.org/10.3390/jcm12216798
work_keys_str_mv AT escobarcarlos currentroleofslgt2inhibitorsinthemanagementofthewholespectrumofheartfailurefocusondapagliflozin
AT pascualfigaldomingo currentroleofslgt2inhibitorsinthemanagementofthewholespectrumofheartfailurefocusondapagliflozin
AT manzanoluis currentroleofslgt2inhibitorsinthemanagementofthewholespectrumofheartfailurefocusondapagliflozin
AT nunezjulio currentroleofslgt2inhibitorsinthemanagementofthewholespectrumofheartfailurefocusondapagliflozin
AT camafortmiguel currentroleofslgt2inhibitorsinthemanagementofthewholespectrumofheartfailurefocusondapagliflozin